March 6, 2024Open Access

An Open-label Phase 2 Study of Eneboparatide, a Novel PTH Receptor 1 Agonist, in Hypoparathyroidism

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Hypoparathyroidism is a rare disorder characterized by a deficiency in PTH resulting in hypocalcemia, hyperphosphatemia, and hypercalciuria. Eneboparatide is an investigational peptide agonist of the PTH1 receptor for the treatment of chronic hypoparathyroidism (HP).

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Takács et al. (Wed,) studied this question.

synapsesocial.com/papers/68e75683b6db6435876ce43c https://doi.org/https://doi.org/10.1210/clinem/dgae121

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling2015 · 298 citations
2Elevated admission serum calcium phosphate product as an independent risk factor for acute kidney injury in hospitalized patients2019 · 21 citations
3Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study2013 · 304 citations
4Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety2019 · 77 citations
5Phosphate Balance and CKD–Mineral Bone Disease2021 · 69 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo